Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a pioneer in RNA interference (RNAi) therapeutics, has unveiled promising results from the HELIOS-B Phase 3 study of vutrisiran, a groundbreaking investigational treatment for ATTR amyloidosis with cardiomyopathy (ATTR-CM). The findings were showcased in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024 and simultaneously published […]
Japanese biotech company GNI Group has announced it will cease enrolment of new patients in its Phase 2 liver fibrosis trial for the drug candidate F351 in China. This decision follows a recommendation from an independent data monitoring committee (IDMC) based on positive efficacy results achieved to date. As of now, 175 out of the […]
California-based Five Prime Therapeutics and Chinese biopharma Zai Lab have initiated a pivotal Phase 3 trial of bemarituzumab (FPA144) in combination with chemotherapy for patients with advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer. The trial, named FIGHT, represents a significant milestone in the development of targeted therapies for these challenging cancers. The FIGHT […]
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients with treatment-resistant depression. The trial’s results revealed that esketamine did not meet its primary endpoint, sparking concern among industry experts and stakeholders. The late-stage study assessed the efficacy of two […]
German pharmaceutical giant Boehringer Ingelheim has announced a significant milestone in the treatment of moderate-to-severe chronic plaque psoriasis. Their drug, Cyltezo, a biosimilar to AbbVie’s renowned psoriasis medication Humira (Adalimumab), has demonstrated clinical equivalence in a pivotal phase 3 trial, known as NCT 02850965. The trial successfully met its primary endpoint, which was the proportion […]
In a significant development in the fight against liver cancer, South Korean biotech company SillaJen, in partnership with Hong Kong-based Lee’s Pharmaceutical, has announced the enrollment of the first patient in China for their phase 3 trial, named PHOCUS. This trial will assess the oncolytic immunotherapy Pexa-Vec for the treatment of advanced liver cancer and […]
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals have announced successful outcomes from their phase 3 study of fasinumab, a nerve growth factor (NGF) antibody, in patients suffering from chronic pain due to osteoarthritis (OA) of the knee or hip. The study met both co-primary endpoints and all key secondary endpoints, signaling a potential new treatment option […]
Lilly’s breast cancer drug, abemaciclib given in combination with fulvestrant has met its primary endpoint of progression-free survival (PFS) in a phase 3 breast cancer trial.
Indianapolis-based pharmaceutical giant Lilly has announced positive outcomes from its phase 3 clinical trial, MONARCH 2, involving its innovative breast cancer treatment, abemaciclib, in combination with fulvestrant. This trial marks a significant advancement in the treatment of hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Groundbreaking Results in Cancer Treatment The […]
Check out details of Astrazeneca Ovarian Cancer Drug, Lynparza which in a phase 3 trial has been demonstrated to have improved survival of patients treated with Lynparza Ovarian Cancer Tablets.
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for patients with germline BRCA-mutations (gBRCA). This breakthrough offers new hope for patients with relapsed disease who have previously not responded to platinum-based chemotherapy. Breakthrough in Ovarian Cancer Treatment The trial […]
Roche breast cancer drug, Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy has been demonstrated in a phase 3 trial to have cut the risk of disease recurrence besides increasing the life span of patients with an aggressive form of early breast cancer.
Roche has announced promising results from the APHINITY trial, a crucial Phase 3 study evaluating Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy. This drug cocktail has been shown to significantly reduce the risk of disease recurrence and extend the lifespan of patients with an aggressive form of early breast cancer. Groundbreaking Results in […]
